Clearmind Medici Stock Price, News & Analysis

Clearmind Medicine (NASDAQ: CMND) has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD). The trial will be conducted at Yale School of Medicine's Department of Psychiatry under Dr. Anahita Bassir Nia's leadership. This FDA-regulated clinical program aims to evaluate the safety, tolerability, and efficacy of CMND-100 in reducing alcohol cravings and consumption among individuals with moderate to severe AUD.

The development addresses a significant global health issue, as alcohol consumption causes 2.6 million deaths annually worldwide and represents 4.7% of global deaths. Current AUD treatments face challenges including high costs, low efficacy (less than 30%), and poor patient compliance due to side effects.

Clearmind Medicine (NASDAQ: CMND) has signed a non-binding term sheet with Dr. Glitter Pty to develop and commercialize a novel MEAI-based alcohol substitute using ActivCrystal™ technology. The collaboration aims to create a product that replicates alcohol's sensations without health risks or hangovers.

The ActivCrystal™ technology encapsulates active ingredients in tasteless, odorless crystals made from natural ingredients that can be sprinkled on meals. Upon finalizing a definitive agreement, the product will allow users to add MEAI-based crystals to their choice of beverage or food with adjustable dosage.

This partnership represents a strategic move in Clearmind's efforts to introduce MEAI to global markets as a solution to combat alcohol misuse.

Clearmind Medicine Inc. (Nasdaq: CMND) has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, a MEAI-based treatment for alcohol use disorder (AUD). This approval marks the second clinical site for the multinational, multi-center trial, which will assess the safety, tolerability, and pharmacokinetics of CMND-100.

The trial will take place at Johns Hopkins University, Yale School of Medicine, and IMCA Center in Israel. Clearmind has already secured FDA approval for its Investigational New Drug (IND) application in the U.S. and approval from the Israeli Ministry of Health.

The primary endpoint of the trial is to determine the tolerable dose and evaluate the safety, pharmacokinetics, and pharmacodynamics of CMND-100. This milestone brings Clearmind closer to offering a potential solution for AUD, which is a major global health issue and the most common substance use disorder among people aged 12 and older in the U.S.

Clearmind Medicine Inc. (Nasdaq: CMND) has announced the publication of an international patent application for a pioneering combination therapy of Ibogaine and N-Acylethanolamines. This innovative treatment, developed in collaboration with SciSparc (Nasdaq: SPRC), aims to enhance safety and efficacy in mental health and addiction care.

Ibogaine, derived from the Tabernanthe iboga shrub, has shown promise in treating various substance use disorders. The combination with N-Acylethanolamines, including Palmitoylethanolamide (PEA), is expected to further improve the therapy's effectiveness and safety profile. This development underscores Clearmind's commitment to leadership in the psychedelics space and its focus on providing safe solutions for unmet mental health needs.

Clearmind Medicine Inc. (Nasdaq: CMND) has filed an international patent application for innovative psychedelic compounds designed to treat post-traumatic stress disorder (PTSD) and other mental health conditions. This application is part of Clearmind's collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem. The compounds were invented by Professors Rami Yaka, Ahmed Masaewa, and Avi Priel.

The global PTSD treatment market, valued at $16.8 billion in 2023, is projected to reach $27.37 billion by 2033. Current PTSD treatments offer efficacy, and FDA-approved drugs often come with side effects. Clearmind aims to develop effective and safe next-generation psychedelic compounds to significantly improve patients' quality of life.

Clearmind Medicine Inc. (Nasdaq: CMND) has announced the publication of an international patent application for a novel combination treatment using MDMA and N-Acylethanolamines. This innovative approach aims to enhance safety and efficacy in mental health and addiction treatments. The patent is part of Clearmind's collaboration with SciSparc (Nasdaq: SPRC), focusing on integrating psychedelic molecules with N-Acylethanolamines, including Palmitoylethanolamide (PEA).

Dr. Adi Zuloff-Shani, CEO of Clearmind, emphasized that this combination therapy addresses FDA safety concerns about MDMA by potentially reducing its dosage while maintaining therapeutic efficacy. The company has filed thirteen patents related to this collaboration in various global jurisdictions, demonstrating their commitment to developing innovative treatments for mental health disorders and addictions.

Clearmind Medicine Inc. (Nasdaq: CMND) has announced the publication of its patent application for innovative combinations of Ketamine and N-Acylethanolamines. This is a result of their ongoing collaboration with SciSparc (Nasdaq: SPRC). The companies are researching combination therapies integrating SciSparc's Palmitoylethanolamide (PEA) with Clearmind's psychedelic molecule MEAI, targeting addictions, weight loss, and mental health disorders.

To date, thirteen patents related to this collaboration have been filed globally. The goal is to develop treatments that maintain effectiveness while reducing doses and minimizing side effects. This approach could potentially address concerns associated with FDA-approved ketamine treatments, which require strict usage guidelines and close supervision due to potential side effects and abuse risks.

Clearmind Medicine Inc. (Nasdaq: CMND) has received a new patent approval from the United States Patent and Trademark Office for its MEAI-based binge behavior regulator program. The patent covers methods of regulating alcoholic beverage consumption and controlling binge behavior through the administration of amine aminoindane, including 5-methoxy-2-aminoindan (MEAI), the company's innovative psychedelic molecule.

This approval strengthens Clearmind's intellectual property portfolio, which now includes 29 granted patents across 19 patent families in key jurisdictions such as the U.S., Europe, China, and India. MEAI is a novel psychoactive molecule that reduces the desire to consume alcohol while providing a mild euphoric, alcohol-like experience. Clearmind's MEAI-based flagship treatment targets Alcohol Use Disorder (AUD) and weight loss, with potential applications in treating binge drinking.

Clearmind Medicine Inc. (Nasdaq: CMND) has announced the submission of an international patent application for generation 3.0 psychedelic compounds to treat mental disorders. This application is part of the company's ongoing collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem. The patent, developed by Prof. Dmitry Tsvelikhovsky, covers new psychedelic compounds, their preparation methods, and therapeutic uses.

The PCT submission allows Clearmind to proceed with national phase applications in major jurisdictions like the US, Europe, China, and India. Dr. Adi Zuloff-Shani, CEO of Clearmind, emphasized the potential of these advanced molecules to offer improved therapeutic options for patients with mental disorders. Clearmind, a clinical-stage psychedelic pharmaceutical biotech company, focuses on developing novel psychedelic-derived therapeutics for underserved health problems, including alcohol use disorder.